Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Amortization of Deferred Charges (2019 - 2025)

Wave Life Sciences (WVE) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges rose 13.53% year-over-year to $1.4 million, compared with a TTM value of $5.4 million through Dec 2025, up 13.53%, and an annual FY2025 reading of $5.4 million, up 13.53% over the prior year.
  • Amortization of Deferred Charges was $1.4 million for Q4 2025 at Wave Life Sciences, up from $1.4 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q4 2025 and bottomed at $512000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 5 years is $1.0 million, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Amortization of Deferred Charges surged 75.27% in 2022, then increased 10.68% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $759000.0 in 2021, then increased by 29.51% to $983000.0 in 2022, then grew by 12.0% to $1.1 million in 2023, then rose by 13.44% to $1.2 million in 2024, then rose by 13.53% to $1.4 million in 2025.
  • Business Quant data shows Amortization of Deferred Charges for WVE at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.3 million in Q2 2025.